Di Zhao, Ph.D.
Areas of Research
- Prostate Cancer
- Targeted Therapy
Dr. Zhao’s laboratory in the Experimental Radiation Oncology (ERO) department is interested in the functional genomics of prostate cancers with two primary directives: (1) understanding how oncogenic signaling pathways and tumor microenvironment regulate cancer development and metastasis, and (2) searching for biomarkers and context-specific therapeutic targets for personalized cancer medicine.
Shi W, Wang Y, Zhao Y, Kim JJ, Li H, Meng C, Chen F, Zhang J, Mak DH, Van V, Leo J, St Croix B, Aparicio A, Zhao D. Immune Checkpoint B7-H3 is a Therapeutic Vulnerability in Prostate Cancer Harboring PTEN and TP53 Deficiencies. Sci Transl Med 15(695):eadf6724, 5/2023. e-Pub 5/2023. PMID: 37163614.
Li H, Gigi L, Zhao D. CHD1, a multifaceted epigenetic remodeler in prostate cancer. Frontiers in Oncology. 13. doi: 10.3389/fonc.2023.1123362, 1/2023. e-Pub 1/2023. PMID: 36776288.
CPRIT Recruitment of First-Time Tenure-Track Faculty Award
Explore Novel Therapeutic Targets for Advanced Prostate Cancer Harboring PTEN loss
NIH/NCI - 1R01CA275990-01
Novel Approaches Targeting B7-H3 in Castration-resistant Prostate Cancer
Prostate Cancer Foundation Challenge Award
Targeting B7-H3 in Aggressive Variant Prostate Cancer
The University of Texas MD Anderson Cancer Center Faculty Scholar Award
Novel Oncogenic Substrate of SPOP Reveals Therapeutic Vulnerability in Metastatic Cancers